» Articles » PMID: 8008709

Hydrogen Bonding Potential As a Determinant of the in Vitro and in Situ Blood-brain Barrier Permeability of Peptides

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1994 Mar 1
PMID 8008709
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

With the exception of various central nervous system (CNS)-required nutrients for which specific, saturable transport systems exist, the passage of most water-soluble solutes through the blood-brain barrier (BBB) is believed to depend largely on the lipid solubility of the solutes. Most peptides, therefore, do not enter the CNS because of their hydrophilic character. Recently, utilizing homologous series of model peptides and Caco-2 cell monolayers as a model of the intestinal mucosa, it was concluded that the principal determinant of peptide transport across the intestinal cellular membrane is the energy required to desolvate the polar amide bonds in the peptide (P. S. Burton et al., adv. Drug Deliv. Rev. 7:365, 1991). To determine whether this correlation can be extended to the BBB, the permeabilities of the same peptides were determined using an in vitro as well as an in situ BBB model. The peptides, blocked on the N- and C-terminal ends, consisted of D-phenylalanine (F) residues: AcFNH2, AcF2NH2, AcF3NH2, AcF2(NMeF)NH2, AcF(NMeF)2NH2, Ac(NMeF)3NH2, and Ac(NMeF)3NHMe. A good correlation among the permeabilities of these model peptides across the bovine brain microvessel endothelial cell (BBMEC) monolayers, an in vitro model of the BBB, and their permeabilities across the BBB in situ was observed (r = 0.928, P < 0.05). The permeabilities of these peptides did not correlate with the octanol-buffer partition coefficients of the peptides (r = 0.389 in vitro and r = 0.155 in situ; P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Natural and engineered cyclodipeptides: Biosynthesis, chemical diversity, and engineering strategies for diversification and high-yield bioproduction.

Widodo W, Billerbeck S Eng Microbiol. 2024; 3(1):100067.

PMID: 39628525 PMC: 11610984. DOI: 10.1016/j.engmic.2022.100067.


The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications.

Banks W, Rhea E, Reed M, Erickson M Cell Rep Med. 2024; 5(11):101760.

PMID: 39383873 PMC: 11604479. DOI: 10.1016/j.xcrm.2024.101760.


A memory-improving dipeptide, Tyr-Pro, can reach the mouse brain after oral administration.

Cheng L, Tanaka M, Yoshino A, Nagasato Y, Takata F, Dohgu S Sci Rep. 2023; 13(1):16908.

PMID: 37805661 PMC: 10560274. DOI: 10.1038/s41598-023-44161-z.


An amide to thioamide substitution improves the permeability and bioavailability of macrocyclic peptides.

Ghosh P, Raj N, Verma H, Patel M, Chakraborti S, Khatri B Nat Commun. 2023; 14(1):6050.

PMID: 37770425 PMC: 10539501. DOI: 10.1038/s41467-023-41748-y.


Neuroprotective Properties of Oleanolic Acid-Computational-Driven Molecular Research Combined with In Vitro and In Vivo Experiments.

Stepnik K, Kukula-Koch W, Plazinski W, Rybicka M, Gawel K Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765042 PMC: 10536188. DOI: 10.3390/ph16091234.


References
1.
Conradi R, Hilgers A, Ho N, Burton P . The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm Res. 1992; 9(3):435-9. DOI: 10.1023/a:1015867608405. View

2.
Brightman M . Morphology of blood-brain interfaces. Exp Eye Res. 1977; 25 Suppl:1-25. DOI: 10.1016/s0014-4835(77)80008-0. View

3.
Fukui S, Schwarcz R, Rapoport S, Takada Y, Smith Q . Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991; 56(6):2007-17. DOI: 10.1111/j.1471-4159.1991.tb03460.x. View

4.
Pardridge W . Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev. 1986; 7(3):314-30. DOI: 10.1210/edrv-7-3-314. View

5.
Rubin L, Hall D, Porter S, Barbu K, Cannon C, Horner H . A cell culture model of the blood-brain barrier. J Cell Biol. 1991; 115(6):1725-35. PMC: 2289219. DOI: 10.1083/jcb.115.6.1725. View